DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established diseaseALETAHA, D; SMOLEN, J. S.Clinical and experimental rheumatology (Testo stampato). 2003, Vol 21, Num 5, pp S169-S173, issn 0392-856X, SUP31Article

Window of opportunity in early rheumatoid arthritis: Possibility of altering the disease process with early interventionQUINN, M. A; EMERY, P.Clinical and experimental rheumatology (Testo stampato). 2003, Vol 21, Num 5, pp S154-S157, issn 0392-856X, SUP31Article

Factors Associated With the Initiation of Disease-Modifying Antirheumatic Drugs in Newly Diagnosed Rheumatoid Arthritis: A Retrospective Claims Database StudyBONAFEDE, Machaon M. K; FOX, Kathleen M; JOHNSON, Barbara H et al.Clinical therapeutics. 2012, Vol 34, Num 2, pp 457-467, issn 0149-2918, 11 p.Article

Wirtschaftlichkeit von Leflunomid bei sequentieller Basistherapie der rheumatoiden Arthritis in Deutschland : Metabolische Arthropathien = Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany : Metabolic arthropathySCHÄDLICH, P. K; ZEIDLER, H; ZINK, A et al.Zeitschrift für Rheumatologie (Print). 2004, Vol 63, Num 1, pp 59-75, issn 0340-1855, 17 p.Article